Literature DB >> 14961004

Update: adverse events following civilian smallpox vaccination--United States, 2003.

.   

Abstract

During January 24-December 31, 2003, smallpox vaccine was administered to 39,213 civilian health-care and public health workers in 55 jurisdictions to prepare the United States for a possible terrorist attack using smallpox virus. This report updates information on vaccine-associated adverse events among civilians vaccinated since the beginning of the program and among contacts of vaccinees, received by CDC from the Vaccine Adverse Event Reporting System (VAERS) during August 9-December 31.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961004

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  12 in total

Review 1.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

2.  LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Authors:  Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  A case-control study of factors associated with HIV infection among black women.

Authors:  Fatu M Forna; Lisa Fitzpatrick; Adaora A Adimora; Eleanor McLellan-Lemal; Peter Leone; John T Brooks; Gary Marks; Alan Greenberg
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

4.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

5.  The pitfalls of bioterrorism preparedness: the anthrax and smallpox experiences.

Authors:  Hillel W Cohen; Robert M Gould; Victor W Sidel
Journal:  Am J Public Health       Date:  2004-10       Impact factor: 9.308

6.  A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.

Authors:  Cheryl X Zhang; Christian Sauder; Tahir Malik; Steven A Rubin
Journal:  Biologicals       Date:  2009-11-06       Impact factor: 1.856

7.  Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox.

Authors:  Huiyong Wei; Dan Huang; Jeff Fortman; Richard Wang; Linyun Shao; Zheng W Chen
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

Review 8.  Treatment of neuroterrorism.

Authors:  Katharina M Busl; Thomas P Bleck
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

9.  A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus.

Authors:  Gregory D Koblentz
Journal:  mSphere       Date:  2018-03-07       Impact factor: 4.389

10.  Active surveillance documents rates of clinical care seeking due to respiratory illness.

Authors:  Marta Galanti; Devon Comito; Chanel Ligon; Benjamin Lane; Nelsa Matienzo; Sadiat Ibrahim; Atinuke Shittu; Eudosie Tagne; Ruthie Birger; Minhaz Ud-Dean; Ioan Filip; Haruka Morita; Raul Rabadan; Simon Anthony; Greg A Freyer; Peter Dayan; Bo Shopsin; Jeffrey Shaman
Journal:  Influenza Other Respir Viruses       Date:  2020-05-16       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.